All The Most Important News and Updates form the European Respiratory Society International Congress – ERS 2018
September 15, 2018
Obesity is known to be a risk factor for developing asthma but a new study shows that the reverse is also true: people with asthma are more likely to go on to become obese. The new research, presented at the European Respiratory Society International Congress, indicates that those who develop asthma as adults and those who have non-allergic asthma are at the greatest risk of obesity.
The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy in moderate to very severe chronic obstructive pulmonary disease
September 16, 2018
AstraZeneca has announced publication of results from the KRONOS Phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide/ glycopyrronium/ formoterol fumarate) versus dual combination therapies Bevespi Aerosphere (glycopyrronium/ formoterol fumarate), Symbicort Turbuhaler (budesonide/ formoterol fumarate) and PT009 (budesonide/ formoterol fumarate) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) regardless of whether or not they had an exacerbation in the prior year.
September 16, 2018
Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, has announced that preclinical data for AZD1402/PRS-060 were presented at two poster sessions at the European Respiratory Society (ERS) International Congress 2018 in Paris, France. PRS-060, an inhaled IL-4 receptor alpha antagonist, the lead candidate in Pieris’ respiratory collaboration with AstraZeneca, is currently in Phase 1 clinical development.
Paracetamol use in infancy is linked to increased risk of asthma in some teenagers: specific variants in the GST genes seem to play a role in greater susceptibility to lung problems
September 17, 2018
Children who take paracetamol during their first two years of life may be at a higher risk of developing asthma by the age of 18, especially if they have a particular genetic makeup, according to new research presented at the European Respiratory Society International Congress.
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
September 18, 2018
AstraZeneca has announced results from the BORA Phase III extension trial evaluating the long-term safety and efficacy of Fasenra (benralizumab) as an add-on maintenance treatment in patients with severe eosinophilic asthma who had previously completed one of the two pivotal SIROCCO or CALIMA Phase III trials. In the BORA trial, Fasenra given for an additional 56 weeks showed a safety and tolerability profile similar to that observed in the placebo-controlled SIROCCO and CALIMA trials, with no increase in the frequencies of overall or serious adverse events. The improvements in efficacy measures observed with Fasenra in the SIROCCO or CALIMA trials were maintained over the second year of treatment. Patients who were treated with placebo in the SIROCCO or CALIMA trials and subsequently transitioned to Fasenra in the BORA trial experienced improvements in efficacy outcomes consistent with those observed for Fasenra-treated patients in the previous trials.
September 18, 2018
First results from a clinical trial of a procedure to open obstructed airways in patients with chronic obstructive pulmonary disease (COPD) have shown that it significantly reduces problems associated with the disease and is safe.
September 19, 2018
Children who have access to green spaces close to their homes have fewer respiratory problems, such as asthma and wheezing, in adulthood, according to new research presented at the European Respiratory Society International Congress. In contrast, children who are exposed to air pollution are more likely to experience respiratory problems as young adults.Top News from ERS International Congress 2018 last edit: 2018-09-24T18:32:13+00:00 da